Evidence map›Paper›PMID 36591308›Full record

ArticleFrontiers in immunology2022

Tuberculosis alters immune-metabolic pathways resulting in perturbed IL-1 responses.

Alba Llibre, Nikaïa Smith, Vincent Rouilly, Munyaradzi Musvosvi, Elisa Nemes, Céline Posseme, Simbarashe Mabwe, Bruno Charbit, Stanley Kimbung Mbandi, Elizabeth Filander and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 3 countries.

Alba LlibreTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Nikaïa SmithTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Vincent RouillyDATACTIX, Paris, France.
Munyaradzi MusvosviSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Elisa NemesSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Céline PossemeTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Simbarashe MabweSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Bruno CharbitCytometry and Biomarkers UTechS, CRT, Institut Pasteur, Université Paris Cité, Paris, France.
Stanley Kimbung MbandiSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Elizabeth FilanderSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Hadn AfricaSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Violaine Saint-AndréTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Vincent BondetTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Pierre BostSorbonne Université, Complexité du vivant, Paris, France.
Humphrey MulengaSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Nicole BilekSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Matthew L AlbertHIBIO, San Francisco, CA, United States.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative (SATVI), Division of Immunology, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Darragh DuffyTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, France.
South African Tuberculosis Vaccine Initiative · ZAUniversité Paris Cité · FRUniversity of Cape Town · ZAInstitut Pasteur · FRHiFiBiO Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) remains a major public health problem and we lack a comprehensive understanding of how

Indexed as

Interleukin-1Interleukin 1 Receptor Antagonist ProteinTuberculosisBCG VaccineHumansInterleukin-1alphaInterleukin-1betaMetabolic Networks and PathwaysProteomicsBCG VaccineIL1A protein, humanIL1B protein, humanIL1RN protein, humanInterleukin-1Interleukin-1alphaInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinIL-1IL-1raimmunometabolismsystems immunologytuberculosis

Identifiers

PMID36591308
PMCPMC9795069
OpenAlexW4311367688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.